Tocilizumab, the first IL-6 receptor antagonist, has demonstrated efficacy in patients with moderate to severe RA refractory to anti-TNF therapy. International Journal of Clinical Rheumatology
Reduction of elevated tumor necrosis factor (TNF)-alpha levels after infliximab treatment does not predict treatment response in patients with rheumatoid arthritis (RA), according to a report in the November issue of The Journal of Rheumatology. Reuters Health Information
Drugs that inhibit tumor necrosis factor provide considerable benefit in treatment of rheumatoid arthritis; however, there is an unmet medical need for alternative therapies. Nature Clinical Practice Rheumatology
Study indicates meniscal damage as a feature of knee osteoarthritis, independent of knee pain, aching, and stiffness ARTHRITIS & RHEUMATISM Research News Alerts
